KIORA PHARMACEUTICALS, INC. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
KIORA PHARMACEUTICALS, INC. (KPRX) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-06-30 was -$2.08M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-03-31 was -$2.42M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-12-31 was -$6.52M.
- KIORA PHARMACEUTICALS, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-09-30 was $26.81K.
- KIORA PHARMACEUTICALS, INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2025 was -$10.84M, a 401.42% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2024 was $3.59M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.08M 10-Q · filed 2026-08-07 | -$4.50M 10-Q · filed 2026-08-07 | -$11.01M derived: sum of 3 quarters · filed 2026-08-07 | -$10.99M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$2.42M 10-Q · filed 2026-05-08 | -$8.93M derived: sum of 2 quarters · filed 2026-05-08 | -$8.91M derived: sum of 3 quarters · filed 2026-05-08 | -$11.06M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$6.49M derived: sum of 2 quarters · filed 2026-03-25 | -$8.64M derived: sum of 3 quarters · filed 2026-08-07 | -$10.84M 10-K · filed 2026-03-25 |
| 2025-09-30 | $26.81K 10-Q · filed 2025-11-07 | -$2.13M derived: sum of 2 quarters · filed 2026-08-07 | -$4.32M 10-Q · filed 2025-11-07 | -$8.54M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$2.15M 10-Q · filed 2026-08-07 | -$4.35M 10-Q · filed 2026-08-07 | -$8.57M derived: sum of 3 quarters · filed 2026-08-07 | -$11.98M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$2.19M 10-Q · filed 2026-05-08 | -$6.42M derived: sum of 2 quarters · filed 2026-05-08 | -$9.83M derived: sum of 3 quarters · filed 2026-05-08 | -$12.05M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$7.64M derived: sum of 2 quarters · filed 2026-03-25 | -$9.86M derived: sum of 3 quarters · filed 2026-03-25 | $3.59M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$3.41M 10-Q · filed 2025-11-07 | -$5.63M derived: sum of 2 quarters · filed 2025-11-07 | $7.82M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$2.22M 10-Q · filed 2025-08-08 | $11.23M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $13.45M 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |